PARLIAMENTARY DEBATE
Health and Social Care Update - 18 March 2021 (Commons/Commons Chamber)
Debate Detail
Before turning to that, I want to update the House on vaccine supply and the roll-out, and set out the facts, given some of the speculation that we have seen overnight.
Let me set out the position absolutely straightforwardly. Throughout the vaccination programme, the pace of roll-out has always been determined by the availability of supply. As I have said in the House many times, supply is the rate-limiting factor. The process of manufacturing vaccines is complicated and subject to unpredictability. Because we get supplies out into the field so fast, and run a highly lean delivery system, changes in future supply schedules impact on the weekly availability of vaccine. This has been true throughout. We make public commitments to the goals we can reach according to our best estimates of future supply. That supply goes up and down. We are currently, right now, in the middle of some bumper weeks of supply.
We have now reached the milestone of 25 million vaccinations, within the first 100 days of roll-out, and we have therefore been able to open up invitations to all people aged 50 and above. Yesterday, for example, we delivered over half a million vaccines, and we will do so again today. In April, supply is tighter than it is this month, and we have a huge number of second doses to deliver. During April, around 12 million people, including many colleagues in this House, will receive their second dose. These second doses cannot be delayed, as they have to be delivered within 12 weeks of the first dose. In the last week, we have had a batch of 1.7 million doses delayed because of the need to re-test its stability. Events like this are to be expected in a manufacturing endeavour of this complexity, and this shows the rigour of our safety checks.
We also have a delay in a scheduled arrival from the Serum Institute of India. I want to put on the record my gratitude to the Serum Institute of India for the incredible work that it is doing producing vaccine, not just for us in the UK but for the whole world. Its technology and its capability, which has been approved by the Medicines and Healthcare products Regulatory Agency, is remarkable. The Serum Institute of India is producing a billion doses of the Oxford AstraZeneca vaccine this year. It truly is a partnership that we can be proud of. I also want to put on the record my thanks to both AstraZeneca and Pfizer, who have been remarkable partners in this historic endeavour.
We have committed to targets, it is vital to say, to offer the vaccine to everyone aged 50 and over by 15 April and to all adults by the end of July. I can confirm that we are on track to meet both those targets. I also want to clear up some rumours that have been circulating and give people reassurance. There will be no weeks in April with no first doses. There will be no cancelled appointments as a result of supply issues. Second doses will go ahead as planned. Most importantly, the vaccine data published yesterday show the life-saving impact of this vaccine. It is not just that the vaccines are safe; it is that they make you safe. You are much safer having had one. Shortly, the MHRA will be saying more on this matter, which of course it keeps under constant review.
I know the House will also want to hear some good news from Gibraltar. Throughout the crisis, we have provided Gibraltar with personal protective equipment, testing and a sovereign guarantee for its covid spending. We have also provided Gibraltar with vaccines, as we have all other British overseas territories. I am delighted to be able to tell the House that yesterday Gibraltar became the first nation in the world to complete its entire adult vaccination programme. I want to pay tribute to all Gibraltarians for their fortitude during this crisis, and the kind words of Chief Minister Fabian Picardo, who said yesterday:
“The United Kingdom has played a blinder on vaccinations and we have been among the beneficiaries in the British family of nations.”
I agree.
The vaccination programme has been a success thanks to a team spirit across the British family of nations. It has not always been easy; of course there are challenges thrown at us in what is the biggest civilian undertaking in history, which affects every single one of us. The whole House pays tribute to those who have helped make it happen, including Emily Lawson, Kate Bingham, Maddy McTernan, Ruth Todd, Nikki Kanani, Professor Jonathan Van-Tam, Professor Chris Whitty, Sir Patrick Vallance, Wei Shen Lim, Sarah Gilbert, Andy Pollard, Pascal Soriot, my officials in the Department, colleagues across the House, and so many others who have made this a success.
With 25 million people vaccinated and a clear road map out of lockdown, we are taking careful steps out of this pandemic. Now, there are 7,218 people in hospital with covid across the UK, down from a peak of almost 40,000 just seven weeks ago, the rate of hospitalisations has halved in just the past 16 days, and thankfully, the rate at which people are dying has fallen by a third in the last week.
As a result, I can tell the House that we are, from today, writing to all clinically extremely vulnerable people to let them know that shielding will come to an end on 31 March. I thank all those who have shown such fortitude, and all those who have done so much to look after the most vulnerable. The shielding programme truly has been Britain at its best—pulling together to help those most in need.
I know that colleagues in the NHS and social care are beginning, cautiously, to look to the recovery ahead. I know that everyone in this House is proud of the life-saving work we have seen in hospitals across the country. Yet we also know that our battles against covid-19 have meant that there are things that we have not been able to do, such as routine treatments and operations. The challenges of covid are still with us. We must continue to treat patients with the disease and bolster our vital mission of infection control, while also laying the groundwork for a recovery that gets us back to where we need to be.
We have backed the NHS at every point in this pandemic so that it can treat patients, stay safe and save lives, and I am delighted to inform the House that we are backing it again today with a further £6.6 billion of funding for the first half of this coming financial year. This money is in addition to the £3 billion committed at the spending review last November to help the NHS meet the additional costs of covid while, critically, starting the work on the elective recovery ahead.
Due to the pandemic, the waiting list for elective treatment in January was almost 4.6 million, and 304,000 people are waiting more than a year for an operation or diagnostic. Before the pandemic, we had reduced the number of 52-week waits—people waiting more than a year—from 20,000 in 2010 to 1,600. We were in fact on track to get that number to zero before the pandemic hit. This backlog of elective work is an inevitable consequence of the pandemic, and I know that NHS colleagues are as determined as I am to put it right.
We are also putting £594 million towards safe hospital discharge. Over the last year, the NHS’s existing discharge programme freed up over 6,000 beds and, with them, the valuable time of 11,000 NHS staff. We can be grateful that we are seeing so many people leave hospital and that our discharge programme has shown the way forward, ensuring that people can get the very best of care outside of our hospitals, helping them off the wards and into the right settings, with the right support at the right time.
Our £500 million mental health recovery package will help tackle the challenges that the pandemic has wrought in access to mental health services. I can also confirm that we will be extending enhanced discharge arrangements for mental health patients, getting patients safely from hospital into healthy community settings, providing better care and freeing up thousands of beds.
The challenge of mental ill health is so important. We all need to keep looking out for each other and doing all we can to strengthen our mental health. Tackling mental ill health is a core objective of our NHS long-term plan, and this Government are committed to seeing mental health treated on a par with physical health and to delivering on the long-needed reforms that we have set out.
I am equally committed to supporting the vital work of our colleagues in adult social care. Last Monday, we reopened care homes to visitors, with a careful policy of a single regular visitor, who will be tested and wear PPE. I know how important this is, and I know that colleagues will be cheered by the stories we hear each day of more and more residents safely reunited with people they love. It means everything to them.
I can today announce a further £341 million to support adult social care with the costs of infection prevention, control and testing that will make sure that visits are safe for everyone. That takes the total infection control fund and testing support to more than £1.6 billion, alongside the free PPE that care homes receive.
The pandemic has tested our NHS and our social care system like never before. That they have risen to meet the challenges of the past year is down to the incredible dedication and hard work of colleagues—they have our thanks. We will deliver on our commitments. We will build 40 new hospitals. We will hire 50,000 more nurses. We will vaccinate this country ahead of almost all others. We will back our NHS and social care as we build back better for everyone. I commend this statement to the House.
Our constituents will be worried, anxious and disappointed at the news on vaccination last night. It has been an unspeakably horrific year. We have one of the worst death rates in the world and our economy has taken a massive hit. Many key workers under the age of 50, such as teachers and police officers, who through the nature of their work are not at home, are going out and are more exposed to risk, had been hoping that vaccination for them was not far away. Of course, we understand why there will be delays in supply, but this is not fantastic news and nor, frankly, is it expected news.
On Saturday, the Government, or Government sources at least, were briefing The Daily Telegraph about a “bumper boost” and saying that everyone over 40 would be offered their first vaccine by Easter. Last week, the Business Secretary was hinting that all adults could be vaccinated by June, saying:
“There is no reason why we can’t be optimistic.”
On Monday, Nottingham and Nottinghamshire clinical commissioning group began inviting those in their 40s for vaccination, and a similar invitation went out from Bury CCG. We are grateful for the Secretary of State’s update today, but it will be a surprise to many.
The Secretary of State did not mention Moderna supplies today. I understand that supplies from Moderna will start in April. Is there any prospect that, if Moderna supplies come on stream, new appointments can be offered in the light of that?
About 11 million people received their first dose between January and February. I listened carefully to what the Secretary of State said. Can he clarify this for the House and our constituents: is he offering them an absolute guarantee that all those people will get their second dose within the 12 weeks throughout April? Our constituents will be keen to get that absolutely clarified.
The vaccination programme will need to ramp up to about 3.5 million doses a week from May to ensure that everyone under 50 is vaccinated by mid-July. Is the Secretary of State confident that these supply issues will be fixed by May? Is there any prospect of doing more than 3.5 million jabs a week from May? We heard today from Adam Finn of the Joint Committee on Vaccination and Immunisation that infection rates may rise as a result of the delays. Does the Secretary of State anticipate that any of the stages, any of the dates, in the road map for easing out of lockdown will be pushed back, given that we are rightly judging the road map by data, not dates?
On behalf of the official Opposition, I take this opportunity to support the AstraZeneca vaccine. Of course, where people are worried and have concerns, those worries and concerns must be addressed, not dismissed. But this is a concern at the moment. Yesterday, for example, I was told that hundreds of people failed to show for appointments at the ExCeL centre and we think that is because of concerns and misinformation circulating online.
There are parts of the country where infection rates remain relatively high and vaccination rates are relatively low. I see that in my Leicester South constituency. Will the Secretary of State pull together a cross-party taskforce of community and local leaders to look at tackling these vaccine hesitancy issues? I again offer to work with him on that on a cross-party basis.
Children make up about 21% of the population. That is a large segment of the population that will be lacking immunity. Obviously, research and trials are ongoing, but does the Secretary of State have a timeline for when he hopes to vaccinate children? Does he anticipate, for example, being able to vaccinate children this autumn, as Anthony Fauci in the US has suggested could well happen over there? Even as vaccination rolls out, the virus continues to circulate, and new vaccine-evading variants could emerge. We may need booster jabs in the autumn, and the winter will be challenging, which is why driving up vaccinations across the whole of the population is so important.
On the Budget allocations that the Secretary of State has announced for the next six months, I welcome the extra funding, of course, but can he guarantee that the NHS will continue to get additional funding after the six months if it is needed for covid care? As he has said, people are waiting longer for treatment, with more than 300,000 waiting over a year, risking permanent disability or loss of livelihood, and with thousands waiting too long for cancer treatment, risking loss of life. We should not have to choose between cancer care and covid care. We are also facing a mental health epidemic as a consequence of this crisis. Crucially, because of years of underfunding, bed cuts and understaffing, when we entered the pandemic we already had growing waiting lists, our A&Es were in crisis and we were missing cancer targets. Can he tell us when he expects to bring down those waiting lists and meet the various cancer targets again?
Finally, the Secretary of State did not mention NHS pay today. He claps NHS workers and nurses, but he is introducing a real-terms pay cut for our NHS staff. Can he tell us whether he will implement any recommendations of the independent pay review body? If it recommends an increase above 1%, can he assure us that the funding will be additional to what he has announced today? In truth, if he really wants to value NHS staff, he should withdraw that pay cut now.
The right hon. Gentleman asked about supplies from Moderna. We expect supplies from Moderna in the coming weeks, and I am grateful to Moderna for the work that it has done. Of course, we have always been cautious about setting out future supply details, and the experience of the last 24 hours makes me even clearer that it is far better for us to set out clear commitments to the public in terms of when people can be vaccinated. This means that all over-50s now can come forward and that we are committed to and on target to offer vaccinations to all over-50s and groups 1 to 9 by 15 April.
However, we know that supply figures move up and down. We have seen that throughout the roll-out, and it is part of the normal management of this roll-out. The commitment I can give the right hon. Gentleman is that, for those who are coming forward for second doses, those appointments will not be delayed because of these supply issues. Also, appointments that are already made will not be cancelled because of supply issues. I therefore say clearly to any member of the public who is watching: the vaccination programme is on track to meet the targets we have set out, and if you get the call from the NHS—whether you get it through a letter, a text, a telephone call or even, these days, an email—take up the offer and get the jab.
The right hon. Gentleman rightly asked about the road map. We are on track for the dates in the road map, and there is no impact on the road map from the changes to vaccine supply that we have been detailing in the last 24 hours.
The right hon. Gentleman asks about the vaccination of children and the autumn vaccination programme. Neither of these is certain. The vaccination of children is currently being assessed in a number of different clinical trials and it is very important that we consider the results of those before making any decision. It is likely that we will need a vaccination booster programme in the autumn, not least to deal with new variants, but that is again not yet certain.
Finally, I am very glad that the right hon. Gentleman welcomed the extra funding that we are putting into the NHS. He asks whether, after six months, there will be more funding if needed for covid purposes. The Chancellor has been absolutely clear from the start of this crisis that the NHS will get what it needs to deal with covid. That is very important, as is the work to restart the NHS in areas where it has had to be paused and, critically, the work that colleagues across the NHS will be doing to recover the backlog of elective work and make sure that everybody can get their appointments and operations in a timely way on the NHS once more. That is the work of the months ahead and I look forward to supporting NHS colleagues in delivering on it.
One further point is that the Oxford-AstraZeneca vaccine was developed because of UK taxpayers putting the funding into the science, development and clinical trials and because of AstraZeneca, with an incredibly bold and generous decision, which we fully support—but it was their decision—to offer this vaccine around the world at cost. Working with institutes such as the Serum Institute of India, Oxford and AstraZeneca are providing a vaccine for the whole world. They are not taking a profit from it. We are very proud of that fact, and that makes this materially different from other vaccines that have been developed for commercial advantage. I am not against that at all, but let us celebrate what AstraZeneca has done, and it only underlines how important it is for everybody to work together to keep their populations safe.
We also apply that approach to therapeutics, and one of the reasons, alongside the NHS, why we are the only country in the world that has participated in the discovery of all the current therapeutics is our use of that approach. Obviously we are driving it further, and I would be very happy to discuss it with my right hon. Friend.
I want to see a level playing field—whether it is in Harlow, Richmond or Huddersfield. There is some resistance to getting the vaccine in some of our urban centres. I can assure him that I will work with him, and we all will work across the House, to make sure that people know it is so vital to get the vaccine, wherever they live. I hope we can have a good PR effort, working together to do that.
Macmillan also says that there are 37,000 people with cancer who are not even in the system yet. Given the scale of this crisis, will the Secretary of State agree to set out an urgent, ambitious and funded plan to catch up with cancer, so that tens of thousands of people do not unnecessarily lose their lives?
Can the Secretary of State reassure the House that if high-risk people in the top categories come forward for their first dose of the vaccine, they will not be prevented from receiving it as a result of anticipated delays to delivery?
As Sarah is a heroine of the town, her name is today being added in a mayoral ceremony to Kettering’s historic timeline in the marketplace, which commemorates key milestones, achievements and famous local people. Will the Secretary of State join me in congratulating Sarah on that thoroughly well-deserved accolade from her home town, praising her outstanding work and recognising her as a role model for young people everywhere who want to enter a worthwhile career in science?
Contains Parliamentary information licensed under the Open Parliament Licence v3.0.